NO1A NeoProbe Corp.

Navidea Biopharmaceuticals to Announce Third Quarter 2016 Financial Results on November 3, 2016

DUBLIN, Ohio--(BUSINESS WIRE)--

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the third quarter of 2016, on Thursday, November 3, 2016 prior to a conference call with the investment community scheduled at 8:30 a.m. ET.

Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event.

Event:       Navidea Biopharmaceuticals Q3 2016 Financial Results Conference Call
Date/Time: November 3, 2016; 8:30 a.m. ET
Webcast Link:

http://edge.media-server.com/m/p/on2557gm/lan/en

Dial-in Number – US: (855) 897-5884
Dial in Number – Int’l: (720) 634-2940
Conference ID Number: 3723903
Replay:

A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com for 30 days.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. The development activities of the Manocept immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

EN
27/10/2016

Underlying

NO1ANeoProbe Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NeoProbe Corp.

 PRESS RELEASE
Free
NO1A NEOPROBE CORP.

Navidea Biopharmaceuticals Announces Reverse Stock Split

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has approved a one-for-twenty reverse stock split of its issued and outstanding shares of common stock. The reverse split will be effective at 12:01 a.m. (EDT) on April 26, 2019, and shares of the Company’s common stock will begin trading on a split-adjusted basis when the NYSE Am...

April 19, 2019 1 EN
 PRESS RELEASE
Free
NO1A NEOPROBE CORP.

Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid ...

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received feedback from the U.S Food and Drug Administration (“FDA”) regarding the Company’s planned clinical studies that will evaluate joint disease in patients with Rheumatoid Arthritis (“RA”) and monitor patient response to therapy. Clinical Studies in Rheumatoid Arthritis ...

April 8, 2019 1 EN
 PRESS RELEASE
Free
NO1A NEOPROBE CORP.

Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear ...

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Arash Kardan, M.D., will give an oral presentation on the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in June 2019. The presentation is titled “A Phase I/Phase II Study of Intravenously (“IV”) Administered Tc99m Tilman...

April 2, 2019 1 EN
 PRESS RELEASE
Free
NO1A NEOPROBE CORP.

Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other B...

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced execution of a Stock Purchase Agreement (the “Purchase Agreement”) with an existing investor, John K. Scott, Jr. (the “Investor”), pursuant to which the Company will issue to the Investor in a private placement (the “Private Placement”) up to $3.0 million in shares (the “Securities”) of the Company’s common ...

March 22, 2019 1 EN
 PRESS RELEASE
Free
NO1A NEOPROBE CORP.

Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 F...

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year of 2018. Navidea reported total revenues for the quarter of $119,000. Net loss attributable to common stockholders was $3.2 million. “Navidea had a productive quarter as we advanced the business and our novel imaging pipeline,” said Mr. Jed ...

March 7, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch